2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Omics Technologies, Bioinformatics, Computational Biology, Emerging Technologies, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Antibody Therapy, Vaccines, Bispecific Antibody Therapy, Checkpoint Inhibitor, Immunotherapy, Infusion, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Pharmacology, Biological Processes, Apoptosis, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Diseases, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, Fundamental Science, AML, Translational Research, MDS, CMML, Clinical Research, Clinical Trials, Study Population, Human, Adult, Animal Model
PAPER

3246 Acquired resistance to ivosidenib in IDH1-mutant AML drives MCL-1 upregulation and compromises venetoclax sensitivity through aldoc-dependent AKT/GSK3β signaling

Lijuan Hu, Yuchen Zhou, PhD2, Xiaojun Huang, MD,PhD3
1 Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Beijing, China, Beijing University People's Hospital, Beijing, China, National Clinical Research Center for Hematologic Disease, Beijing, China
2 Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Beijing, China, Beijing University People's Hospital, Beijing, China, National Clinical Research Center for Hematologic Disease, Beijing, China
3 Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Beijing, China, Beijing University People's Hospital, Beijing, China, National Clinical Research Center for Hematologic Disease, Beijing, China

The combination of ivosidenib (IVO), a mutant IDH1 inhibitor, and venetoclax (VEN), a BCL-2 inhibitor, has demonstrated clinical efficacy in IDH1-mutant acute myeloid leukemia (AML). However, acquired resistance inevitably emerges in a subset of patients, representing a major clinical challenge. MCL-1 upregulation is a well-established mechanism of VEN resistance in AML. Beyond their canonical metabolic functions, glycolytic enzymes have been increasingly recognized for their non-metabolic roles in regulating apoptosis and drug resistance. Aldolase C (ALDOC), a key enzyme in glycolysis catalyzing the cleavage of fructose-1,6-bisphosphate, has been implicated in chemoresistance in solid tumors, yet its role in AML remains unexplored.

  To investigate whether ALDOC mediates acquired resistance to IVO+VEN in IDH1-mutant AML and to elucidate the underlying molecular mechanism,an IDH1 R132H (c.395G>A) mutant THP-1 cell line was established using CRISPR-Cas9 technology and we developed a model of acquired drug resistance by treating sensitive THP-1 IDH1R132H cells continuously with IVO in culture for a period of 2 months followed by a drug washout period. The resistant phenotype was characterized by flow cytometry-based differentiation (CD14 expression) assays,as CD14 (a marker for monocyte differentiation) no longer shows an increased expression upon induction by IVO.  IVO-resistant IDH1-mutant THP-1 cells exhibited diminished apoptosis upon VEN addition compared to VEN alone. Mechanistically, IVO treatment led to significant upregulation of MCL1 at protein levels without altering MCL1 transcription. Pharmacological inhibition or MCL-1 knockdown by shRNA restores the sensitivity of resistant cells to IVO+VEN. Through RNA sequencing, we found that the glycolytic pathway was significantly activated in IVO-resistant IDH1-mutant THP-1 cells. And through RT-qPCR analysis of the key enzymes in the glycolytic pathway, it was discovered that only the mRNA of ALDOC showed a significant 3-fold increase. Subsequently, through immunoprecipitation and mass spectrometry analysis, we discovered that ALDOC binds glycogen synthase kinase 3-beta (GSK3beta) and acts as a scaffold with the Akt kinase and GSK3beta to facilitate GSK3beta phosphorylation(Ser9), leading to MCL-1 protein stabilization. Immunofluorescence revealed co-localization of ALDOC and GSK3β, suggesting potential physical interaction. Notably, the combination of IVO, VEN, and an ALDOC inhibitor achieved apoptosis levels comparable to IVO plus a MCL-1 inhibitor, effectively reversing acquired resistance. ALDOC knockdown or pharmacological inhibition abolished MCL-1 upregulation and restored sensitivity to IVO+VEN. GSK3β inhibition partially abrogated the sensitizing effect of ALDOC inhibition, confirming that ALDOC acts through the GSK3β-MCL-1 axis. These findings were validated in primary IDH1-mutant AML patient samples and across additional AML cell lines.

Our study identifies ALDOC as a critical mediator of acquired resistance to IVO+VEN in IDH1-mutant AML through a previously unrecognized non-metabolic mechanism: the ALDOC-AKT-GSK3β-MCL-1 signaling axis. Targeting ALDOC represents a promising therapeutic strategy to overcome resistance in this patient population.

Yuchen Zhou, PhD: No relevant conflicts of interest to declare.